| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2013: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
CD90-positive fibroblasts were observed in 93% or more in the analysis of pancreatic stellate cells and this CD90 could be the key surface marker to regulate desmoplasia. In the analysis of pancreatic cancer cells, CD105-positive pancreatic cancer cells showed the specific gene expression of epithelial-mesenchymal transition and these mobility were enhanced by pancreatic stellate cells. In the case of CD166, CD166-negative pancreatic cancer cells showed strong mobility and invasiveness compared with CD166-positive cells. Furthermore, the anti-fibrotic drug "Pirfenidone" inhibited pancreatic cancer desmoplasia mainly contributed by pancreatic stellate cells and it had been suggested that regulation of stroma could suppress progression for pancreatic cancer.
|
